Table 3. Pharmacokinetic Parameters of Amodiaquine and N-Desethylamodiaquine after Oral Administration of Amodiaquine (60 mg/kg) Alone (Group-I) and Intravenous Administration of Myricetin (5 mg/kg) Followed by Oral Administration of Amodiaquine (Group-II) in Ratsa.
| amodiaquine |
N-desethylamodiaquine |
|||
|---|---|---|---|---|
| pharmacokinetic parameters | (group-I) | (group-II) | (group-I) | (group-II) |
| Cmax (ng/mL) | 1030.70 ± 246.80 | 1044.26 ± 121.61 | 370.40 ± 125.05 | 396.49 ± 32.00 |
| Tmax (h) | 3.80 ± 1.35 | 3.90 ± 1.29 | 4.20 ± 0.80 | 3.60 ± 0.81 |
| AUC0–t (ng·h/mL) | 3119.86 ± 414.44 | 4836.65 ± 608.37* | 1313.30 ± 349.54 | 2061.57± 452.16* |
| AUC0–∞ (ng·h/mL) | 4007.08 ± 428.29 | 6419.20 ± 893.58* | 3362.65 ± 667.75 | 3980.79 ± 1273.24* |
| T1/2 (h) | 2.16 ± 0.30 | 2.49 ± 0.85 | 11.65 ± 3.21 | 7.91 ± 3.00 |
| MRT (h) | 5.78 ± 0.70 | 6.32 ± 0.85 | 18.70 ± 4.68 | 12.64 ± 4.42 |
| Vd/F (L/kg) | 49.64 ± 11.02 | 33.92 ± 11.09 | ||
| Cl/F (L/(h kg)) | 15.67 ± 1.65 | 10.08 ± 1.36* | ||
a
Cmax, maximum plasma concentration; Tmax, time to reach Cmax; AUC0–t and AUC0–∞, AUC for plasma concentration from zero to the last measurable plasma sample time and to infinity; T1/2, elimination half-life; MRT, mean residence time; Vd/F, volume of distribution after oral administration; and Cl/F, clearance after oral administration. Data are presented as mean ± SEM (n = 5). *p < 0.05 denotes statistically significant when comparing Group-I versus Group-II.